ESMO 2018 Congress: Highlights in metastatic triple negative breast cancer LBA1 PR
Dr. Peter Schmid reports on key results from ESMO 2018 Congress: LBA1_PR: IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.
Produced by the European Society for Medical Oncology http://www.esmo.org
Watch video ESMO 2018 Congress: Highlights in metastatic triple negative breast cancer LBA1 PR online without registration, duration hours minute second in high quality. This video was added by user European Society for Medical Oncology (ESMO) 20 October 2018, don't forget to share it with your friends and acquaintances, it has been viewed on our site 3,993 once and liked it 20 people.